Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. CVS
stocks logo

CVS

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
102.27B
+4.66%
0.968
-18.69%
99.85B
+5.57%
2.363
+5.02%
104.55B
+5.7%
1.923
+6.23%
Estimates Revision
The market is revising Upward the revenue expectations for CVS Health Corporation (CVS) for FY2025, with the revenue forecasts being adjusted by 1.22% over the past three months. During the same period, the stock price has changed by 4.03%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.22%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.44%
In Past 3 Month
Stock Price
Go Up
up Image
+4.03%
In Past 3 Month
Wall Street analysts forecast CVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVS is 89.93 USD with a low forecast of 75.00 USD and a high forecast of 102.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
Wall Street analysts forecast CVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVS is 89.93 USD with a low forecast of 75.00 USD and a high forecast of 102.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
1 Hold
0 Sell
Strong Buy
Current: 76.750
sliders
Low
75.00
Averages
89.93
High
102.00
Current: 76.750
sliders
Low
75.00
Averages
89.93
High
102.00
Wells Fargo
Stephen Baxter
Overweight
downgrade
$103 -> $102
2025-11-13
Reason
Wells Fargo
Stephen Baxter
Price Target
$103 -> $102
2025-11-13
downgrade
Overweight
Reason
Wells Fargo analyst Stephen Baxter lowered the firm's price target on CVS Health to $102 from $103 and keeps an Overweight rating on the shares. Overall, results in Q3 were solid, but the bull case for HCB in 2025 moderates some on steeper Part D MLR, the firm says. Wells' 2025 EPS estimate increases, with 2026 unchanged and modestly ahead of what CVS framed as a reasonable starting point for guidance.
TD Cowen
Buy
maintain
$99 -> $100
2025-11-03
Reason
TD Cowen
Price Target
$99 -> $100
2025-11-03
maintain
Buy
Reason
TD Cowen raised the firm's price target on CVS Health to $100 from $99 and keeps a Buy rating on the shares. The firm update its estimates following 3Q25 results, where management raised its 2025 adj. EPS guide to $6.55-$6.65 from $6.30-$6.40 and provided preliminary a preliminary 2026 framework
RBC Capital
Outperform
maintain
$81 -> $93
2025-10-30
Reason
RBC Capital
Price Target
$81 -> $93
2025-10-30
maintain
Outperform
Reason
RBC Capital raised the firm's price target on CVS Health to $93 from $81 and keeps an Outperform rating on the shares. The company reported a solid Q3 EPS beat with Medical Benefit Ratio comfortably below expectations after adjusting for prior-period one-time items and trend in the non-continuing ACA exchange business, the analyst tells investors in a research note.
BofA
Buy
maintain
$89 -> $100
2025-10-30
Reason
BofA
Price Target
$89 -> $100
2025-10-30
maintain
Buy
Reason
BofA raised the firm's price target on CVS Health to $100 from $89 and keeps a Buy rating on the shares following what the firm calls "a mixed-to-good" Q3 report. The firm thinks the initial EPS guidance of about $7.07 is "a good starting point with significant catalysts over the next year to revise that figure higher," the analyst tells investors. After the report, BofA increased its 2025 EPS estimate to $6.64 from $6.38 and reduced its 2026 EPS view to $7.09 from $7.34, the analyst noted.
UBS
Buy
upgrade
$79 -> $96
2025-10-24
Reason
UBS
Price Target
$79 -> $96
2025-10-24
upgrade
Buy
Reason
UBS raised the firm's price target on CVS Health to $96 from $79 and keeps a Buy rating on the shares.
Goldman Sachs
initiated
$91
2025-10-14
Reason
Goldman Sachs
Price Target
$91
2025-10-14
initiated
Reason
Goldman Sachs initiated coverage of CVS Health with a Buy rating and $91 price target. The managed care industry faces its most significant underwriting downturn in over 15 years, the analyst tells investors in a research note. Goldman recommends increased exposure to Medicare Advantage as it sees a margin recovery phase beginning in 2026. However, the firm does not see the Medicare Advantage recovery playing out uniformly across the group in 2026. The analyst also sees a longer path to cyclical recovery in Medicaid and the healthcare exchange.
See All Ratings

Valuation Metrics

The current forward P/E ratio for CVS Health Corp (CVS.N) is 11.11, compared to its 5-year average forward P/E of 10.16. For a more detailed relative valuation and DCF analysis to assess CVS Health Corp 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
10.16
Current PE
11.11
Overvalued PE
11.56
Undervalued PE
8.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
9.07
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
9.94
Undervalued EV/EBITDA
8.19

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.30
Current PS
0.00
Overvalued PS
0.39
Undervalued PS
0.21
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress areSelling! The selling amount has increased306.25%over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

CVS News & Events

Events Timeline

(ET)
2025-12-04
09:10:00
JAKKS Pacific Partners with Hershey to Launch New Doll Collection
select
2025-12-02 (ET)
2025-12-02
09:50:00
CVS Pharmacy Settles Healthcare Fraud Lawsuit for $37.76 Million
select
link
2025-11-25 (ET)
2025-11-25
06:20:32
Speaker Johnson cautions that House Republicans oppose ACA subsidies, according to WSJ.
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-04PRnewswire
Aetna Integrates Prior Authorization Process to Enhance Healthcare Efficiency
  • Integrated Authorization Process: Aetna simplifies the prior authorization process by bundling medical procedures and prescriptions into condition-specific packages, which is expected to significantly enhance the efficiency and quality of healthcare services.
  • New Care Model Launch: The Aetna Clinical Collaboration (ACC) program is being implemented in 17 hospitals, projected to reduce 30-day readmission rates and hospital length of stay by 5%, thereby improving care experiences for elderly patients.
  • AI Solutions Implementation: Aetna embeds generative AI in its health app to enhance user experience and simplify healthcare navigation, which is anticipated to boost user satisfaction and engagement.
  • Digital Investment Strategy: As part of CVS Health's $20 billion digital investment, Aetna focuses on optimizing claims processing and client management through technological innovations, further solidifying its leading position in the health insurance market.
[object Object]
Preview
7.0
12-04Benzinga
CVS Settles for $37.8 Million Over Allegations of Years of Incorrect Insulin Refills

  • CVS Health Fraud Allegations: Federal prosecutors allege that CVS Health engaged in improper billing practices related to insulin pens, seeking reimbursement for unnecessary or inaccurately reported refills from federal healthcare programs between 2010 and 2020.

  • Settlement Details: CVS has agreed to a $37.76 million settlement, with $24.4 million going to the federal government and the rest to participating states, while admitting to certain misconduct regarding the reimbursement claims.

  • Inaccurate Reporting Issues: CVS reportedly understated the amount of insulin dispensed, which allowed for premature refills through an auto-refill system, leading to safety concerns for patients due to excess insulin.

  • Management Awareness: Federal officials indicated that CVS management was aware of the over-dispensing issues from internal audits but failed to address them for several years.

[object Object]
Preview
7.0
12-03Newsfilter
CVS Health Settles $37.76 Million Insulin Pen Claims Allegations
  • Settlement Amount: CVS Health will pay $37.76 million to settle allegations of violating the federal False Claims Act between 2010 and 2020 by dispensing excessive insulin pens and improperly obtaining reimbursements from Medicare and other government programs, highlighting significant compliance challenges for the company.
  • Government Compensation: Of the settlement, $24.45 million will go to the federal government, with the remainder distributed to various states, indicating strict regulatory oversight on drug reimbursement compliance that could impact CVS's future financial performance.
  • Internal Allegations: CVS allegedly instructed pharmacy staff to report maximum days-of-supply when dispensing insulin pens to ensure quick prescription fills and reimbursement approvals, a practice that not only harmed patient interests but may also expose the company to increased scrutiny and legal risks.
  • Whistleblower Rewards: The settlement allocates 19.5% of the amount to whistleblowers, reflecting the company's commitment to compliance issues while potentially encouraging more employees to report misconduct, thereby affecting corporate culture and operational transparency.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is CVS Health Corp (CVS) stock price today?

The current price of CVS is 76.75 USD — it has increased 2.33 % in the last trading day.

arrow icon

What is CVS Health Corp (CVS)'s business?

CVS Health Corporation is a health solutions company. The Company's segments include Health Care Benefits, Health Services, Pharmacy & Consumer Wellness and Corporate/Other. Health Care Benefits segment offers a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, PDPs and Medicaid health care management services. Health Services segment provides a full range of pharmacy benefit management (PBM) solutions through its CVS Caremark operations and delivers health care services in its medical clinics, virtually, and in the home. Pharmacy & Consumer Wellness segment dispenses prescriptions in its CVS Pharmacy retail locations and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, diagnostic testing and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise.

arrow icon

What is the price predicton of CVS Stock?

Wall Street analysts forecast CVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVS is 89.93 USD with a low forecast of 75.00 USD and a high forecast of 102.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is CVS Health Corp (CVS)'s revenue for the last quarter?

CVS Health Corp revenue for the last quarter amounts to 102.87B USD, increased 7.80 % YoY.

arrow icon

What is CVS Health Corp (CVS)'s earnings per share (EPS) for the last quarter?

CVS Health Corp. EPS for the last quarter amounts to -3.13 USD, decreased -4571.43 % YoY.

arrow icon

What changes have occurred in the market's expectations for CVS Health Corp (CVS)'s fundamentals?

The market is revising Upward the revenue expectations for CVS Health Corporation (CVS) for FY2025, with the revenue forecasts being adjusted by 1.22% over the past three months. During the same period, the stock price has changed by 4.03%.
arrow icon

How many employees does CVS Health Corp (CVS). have?

CVS Health Corp (CVS) has 300000 emplpoyees as of December 05 2025.

arrow icon

What is CVS Health Corp (CVS) market cap?

Today CVS has the market capitalization of 97.43B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free